|
8141 |
The reward for placebos: mechanisms underpinning placebo-induced effects on motor performance
Enthalten in European journal of applied physiology Bd. 122, 25.8.2022, Nr. 11, date:11.2022: 2321-2329
|
|
|
|
8142 |
The Right Patients for the Drug: Managing the Placebo Effect in Antidepressant Trials
Enthalten in BioSocieties Bd. 2, 1.5.2007, Nr. 1, date:3.2007: 57-71
|
|
|
|
8143 |
The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection—study protocol for a two-stage randomised phase II trial
Enthalten in Trials Bd. 23, 5.4.2022, Nr. 1, date:12.2022: 1-26
|
|
|
|
8144 |
The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis
Enthalten in Systematic Reviews Bd. 12, 30.3.2023, Nr. 1, date:12.2023: 1-10
|
|
|
|
8145 |
The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double-blind, placebo-controlled dietary study
Enthalten in BMC nutrition Bd. 10, 4.1.2024, Nr. 1, date:12.2024: 1-13
|
|
|
|
8146 |
The role of superstition in the placebo effect on memory performance
Enthalten in Cognitive processing Bd. 22, 6.7.2021, Nr. 3, date:8.2021: 553-558
|
|
|
|
8147 |
The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
Enthalten in BMC clinical pharmacology Bd. 3, 13.11.2003, Nr. 1, date:12.2003: 1-8
|
|
|
|
8148 |
The Safety, Tolerability, and Pharmacokinetics of ALT-BB4 (A Novel Recombinant Hyaluronidase): A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study in Healthy Volunteers
Enthalten in Dermatology and therapy Bd. 15, 2.9.2025, Nr. 11, date:11.2025: 3301-3311
|
|
|
|
8149 |
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
Enthalten in Journal of cachexia, sarcopenia and muscle Bd. 2, 2.8.2011, Nr. 3, date:9.2011: 153-161
|
|
|
|
8150 |
The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)
Enthalten in BMC pharmacology & toxicology Bd. 16, 2.9.2015, Nr. 1, date:12.2015: 1-2
|
|
Administration
